No Data
Kura Oncology to Report Third Quarter 2024 Financial Results
UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus
Express News | Kura Oncology Inc - Proof-of-Concept Study of Ziftomenib Plus Imatinib to Begin in 1H 2025
Express News | Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (Gist)
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $32
UBS Initiates Kura Oncology(KURA.US) With Buy Rating, Announces Target Price $27
No Data
No Data
